The association between toenail selenium and breast cancer was studied in a prospective study on diet and cancer among 62,573 Dutch women aged 55-69 years that started in September 1986. The analysis was based on 355 breast cancer cases, detected during 3.3 years of follow-up (1986-1989), for whom selenium data were available. Selenium levels were significantly lower among cases diagnosed early during follow-up. After exclusion of cases that occurred in the first year of follow-up, multivariable-adjusted rate ratios of breast cancer in increasing quintiles of selenium were 1.00, 0.90, 0.76, 0.86, and 0.91 (trend p = 0.618). The authors found no evidence for an inverse association between selenium status and breast cancer. Am J Epidemiol
marker of selenium intake, was significantly lower in breast cancer cases compared with controls, this was not true in another study (12) . Selenium in long-term markers, such as erythrocytes (12, 13) or toenails (12) , has also not been found to be significantly associated with breast cancer. In prospective cohort studies (14) (15) (16) (17) (18) (19) (20) , where prediagnostic selenium status can be measured and information bias can be avoided, most studies have failed to find an association between breast cancer risk and serum or toenail selenium levels. The latter marker has been suggested as an indicator of long-term selenium status (21, 22) , and it reflects differences in selenium intake (23, 24) . We studied the relation between toenail selenium levels and the risk of breast cancer in a prospective cohort study in the Netherlands, a country with a high incidence of breast cancer (25) and a moderate selenium intake (26) . In addition, we evaluated the importance of exclusion of cases diagnosed early during follow-up.
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MATERIALS AND METHODS
The characteristics of the Netherlands Cohort Study on diet and cancer and the method of cancer follow-up have been described previously (27, 28) . Briefly, the study started in 1986 when 58,279 men and 62,573 women aged 55-69 years were enrolled in the cohort. At baseline, cohort members completed a self-administered questionnaire on usual dietary intake and potential confounders and also provided toenail clippings. This took place for the entire cohort in the period September to October 1986. Following a case-cohort approach for analysis of the data, a subcohort of 3,500 subjects (1,688 men and 1,812 women) was randomly sampled from the cohort after the baseline exposure measurement. The subcohort has been followed biennially for vital status information in order to estimate the accumulated person-time in the cohort. Incident cancer cases that occurred in the cohort have been identified by record linkage to cancer registries and a pathology register. The analysis in this report is restricted to the cancer incidence in the recently completed 3.3-year follow-up period from September 1986 to December 1989. The completeness of cancer follow-up was estimated to be 95 percent (29) . In these 3.3 years of follow-up, a total of 553 breast cancer cases were detected among the cohort of 62,573 women. After exclusion of incident cases who reported a history of cancer other than skin cancer in the baseline questionnaire (n = 67) and cases with in situ carcinoma of the breast (n = 15), 471 microscopically confirmed incident breast cancer cases were available for analysis. After exclusion of prevalent cases with cancer other than skin cancer from the female cohort of 1,812 as well, 1,716 subjects remained in this group. Toenail clippings had been provided at baseline by 374 breast cancer cases (79.4 percent) and 1,322 female subcohort members (77.0 percent). Problems with the detection of toenail selenium (interference by other elements such as calcium) occurred in 7 and 9 of these 374 and 1,322 specimens, respectively. Another 12 and 65 specimens were excluded from the breast cancer and subcohort groups, respectively, because the specimens weighed less than 10 mg, which would yield unreliable selenium measurements. Thus, toenail selenium data were available for analysis from 355 breast cancer cases and 1,248 female subcohort members. Toenail selenium levels were determined with instrumental neutron activation analysis. Each analytical batch contained toenail specimens from cancer patients and subcohort members, and specimens were analyzed in a manner blinded with respect to case or subcohort status. The analysis method and evaluation of accuracy and precision have been described elsewhere (30) .
Data analysis
Mean toenail selenium levels of breast cancer cases and subcohort were compared, as well as the mean levels of cases, grouped according to year of follow-up and according to anatomic extent of the primary tumor (T), assessed according to the criteria of the tumor, node, metastasis (TNM) tumor staging classification. Next, age-stratified and multivariate case-cohort analyses (29, 31) were conducted, which took into account the additional variance introduced by the subcohort sampling. For these analyses, toenail selenium levels were categorized into quintiles according to the distribution in the female subcohort. In the multivariate analyses, adjustment was made for the effects of traditional breast cancer risk factors and intake of energy and alcohol. To evaluate the potential influence of prediagnostic breast cancer on toenail selenium levels, analyses were also conducted after exclusion of cases that occurred in the first year of follow-up. The analyses were carried out using the GLIM statistical package (32, 33) .
RESULTS
The mean (± standard deviation (SD)) toenail selenium level in breast cancer cases was 0.569 (±0.104) /xg/g, while in the female subcohort members the mean value was 0.575 (±0.109) jig/g (table 1 ). When t f test between strata, based on In-transformed toenail selenium levels.
t Reference category. § T1, tumor =£2 cm; T2,2-5 cm; T3, >5 cm; T4, any size with direct extension to chest wall or skin.
cases were categorized with respect to the year of follow-up in which they were diagnosed, mean toenail selenium levels were higher toward later years of follow-up. Cases in the first and second year of follow-up had significantly lower toenail selenium levels than cases diagnosed in subsequent years. For 314 of the 355 breast cancer cases, information on the extent of the primary tumor was available. Cases with tumor extent T3 (>5 cm) or T4 (any tumor size with direct extension to chest wall or skin) had significantly lower mean selenium levels than cases with tumor extent Tl (^2 cm) or T2 (2-5 cm). However, T2 cases had higher mean selenium levels than Tl cases (table 1) . Although the proportion of cases with T3 or T4 tumors was somewhat higher in the first 2 years of follow-up, no significant association between tumor extent and year of follow-up was found (data not shown). We also compared toenail selenium levels among subcohort members who were analyzed in batches together with cases that occurred in the first year of follow-up with the levels among subcohort members whose toenails were analyzed with cases that were diagnosed later. The mean (±SD) selenium level in the former set of subcohort members (n = 327) was 0.575 (±0.133) /xg/g compared with a mean of 0.574 (±0.099) for the latter group of subcohort members (n = 921), indicating that the apparent preclinical disease effect was not due to intralaboratory variation.
When an age-stratified analysis of toenail selenium and breast cancer was conducted, the Mantel-Haenszel rate ratios were somewhat decreased in the upper four quintiles compared with the lowest quintile, but only the rate ratio of 0.64 in the third quintile was significantly different from one and the test for trend was not statistically significant (table 2) .
When the association between toenail selenium and breast cancer risk was analyzed in a multivariate model containing terms for non-dietary breast cancer risk factors, energy intake, and alcohol use, the rate ratios for increasing quintiles of toenail selenium were estimated at 1.00,0.72,0.62, 0.68, and 0.84, respectively. Again, the rate ratio in the third quintile was significantly below the null value, but the trend was not significant (trend p = 0.307). When a similar model was fitted after exclusion of cases diagnosed in the first year of follow-up, the rate ratios in the upper four quintiles were closer to the null value (0.90, 0.76, 0.86, and 0.91, respectively; trend p = 0.618) and the rate ratio in the third quintile was no longer significant. Additional exclusion of cases that occurred in the second year of follow-up again yielded no association between selenium and breast cancer (trend/? = 0.577). If we limited our analysis to the first year of follow-up (thus mimicking a case-control study), the rate ratio estimates for increasing quintiles of toenail selenium would be 1.00, 0.38,0.36,0.34, and 0.71 (trendp = 0.218), with the middle three estimates being significantly different from unity (table 2) . When we compared women in quintiles 2-5 with the lowest quintile, the rate ratio was 0.71 (95 percent confidence interval (CI) 0.51-0.99) in the whole data set, but after exclusion of cases from the first year of follow-up, the rate ratio was 0.85 (95 percent Cl 0.58-1.24). Thus, when we do not assume a linear association, the results indicate that selenium levels are not significantly associated with breast cancer risk after exclusion of cases from the first year of follow-up.
Following our observations on effect modification of the association between toenail selenium and lung cancer by the intake level of antioxidant vitamins beta-carotene and vitamin C (34), we also evaluated whether the association with breast cancer depended on intake of these antioxidants. However, the results were not unequivocal (table 3) . Whereas the inverse association with selenium became stronger (but not significant) in those women with a relatively low beta-carotene intake, in women with a relatively low vitamin C intake, the association with selenium became positive. Thus, the data do not consistently show that the inverse association with selenium is stronger when intake of other antioxidants is low.
DISCUSSION
We did not find a significant inverse association between toenail selenium level and breast cancer risk in this prospective study among postmenopausal women, after exclusion of cases that occurred in the first year of follow-up. Our findings on lowered toenail selenium levels in cases that occurred early in the follow-up period are in contrast with those of Hunter et al. (20) , who reported no influence of prediagnostic breast cancer on toenail selenium levels. However, in another cohort study, prevalent breast cancer cases showed slightly lower toenail selenium concentrations than incident cases (19) . The possible influence of prediagnostic breast cancer on lowering selenium status is also in accordance with observations on normal and tumor tissue of breast cancer patients, indicating a sequestration of selenium by the tumor tissue (35) . Furthermore, it has been found in casecontrol studies that plasma and erythrocyte selenium levels were lowered only in cases with large tumors (12) and that selenium levels were inversely associated with breast cancer stage (10) . Given the possible modulation of selenium status by prediagnostic breast cancer, the results of case-control studies are difficult to interpret. Casecontrol studies on serum selenium have shown varying results (9-12); a possible explanation for this variation might be a dissimilarity in the stage distribution of breast cancer patients between the various studies or timing of blood collection. Case-control studies that have measured erythrocyte selenium showed no association with breast cancer (12, 13) . Toenail selenium was modestly inversely related to breast cancer in a recent case-control study (12) . When we simulated a case-control study by limiting our analysis to early cases, we also found an inverse association with toenail selenium; this result might be partly attributable to a somewhat higher proportion of T3 and T4 tumors in this subgroup.
Two prospective studies on toenail selenium and breast cancer have been published, both using a nested case-control analysis. Hunter et al. (20) found no association between toenail selenium and breast cancer in their study, which included 434 incident breast cancer cases out of a cohort of 62,641 US nurses after a follow-up of 4.4 years; there was also no association when premenopausal and postmenopausal women were analyzed separately. The study by van Noord et al. (19) among 8,760 premenopausal women (27 incident cases after 2 years of follow-up) also showed no association with selenium levels. Apart from these toenail studies, there have been a number of prospective, nested case-control studies that have used serum selenium and that have reported specific results on breast cancer risk (14) (15) (16) (17) (18) . The follow-up periods of these studies ranged from 5 years (14) to over 10 years (15, 18) . None of these serum studies showed a significant association between serum selenium and breast cancer risk, but it should be mentioned that the number of breast cancer cases in most of the studies was too small to perform statistically meaningful analyses for this site (14) (15) (16) (17) . The toenail selenium levels found in Dutch studies (12, 19, 30) are lower than those found in a comparable study from the United States (20) . It might be that an association with selenium is only apparent at still lower levels. In a Finnish cohort, with relatively low serum selenium levels, an increased risk was only observed for women in the lowest selenium quintile (18) , which could suggest the presence of a threshold selenium level below which breast cancer risk is affected (36) .
In conclusion, we found no evidence for an inverse association between selenium status, as measured by toenail selenium levels, and the risk of breast cancer. The rela-tively low toenail levels observed among cases that occurred early during follow-up suggest the need to interpret case-control studies on selenium and breast cancer with caution, because of possible information bias.
